Protalix BioTherapeutics (PLX) Income from Continuing Operations (2010 - 2026)
Protalix BioTherapeutics' (PLX) quarterly Income from Continuing Operations came in at 18388000.0 in Q1 2026, up 608.1% year-on-year from 2596822.45 in Q1 2025, and up 613.06% quarter-over-quarter from 3584000.0 in Q4 2025.
Protalix BioTherapeutics (PLX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 18388000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 608.1% year-over-year to 18388000.0 in Q1 2026; TTM through Mar 2026 was 17613000.0, a 108.29% increase from a year earlier, with the FY2025 full-year figure at 4684000.0, down 162.62% from the prior year.
- Income from Continuing Operations rose to 18388000.0 in Q1 2026 per PLX's latest filing, from 3584000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 18388000.0 in Q1 2026 and bottomed at 20124000.0 in Q4 2023.
- The 5-year median for Income from Continuing Operations is 2286000.0 (2022), against an average of 107117.65.
- Across the five-year window, Income from Continuing Operations slumped 526.92% in 2023 and surged 608.1% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 3210000.0 in 2022, then slumped by 526.92% to 20124000.0 in 2023, then soared by 153.7% to 10806000.0 in 2024, then slumped by 133.17% to 3584000.0 in 2025, then jumped by 613.06% to 18388000.0 in 2026.
- Per Business Quant, the three latest PLX Income from Continuing Operations figures stand at 18388000.0 (Q1 2026), 3584000.0 (Q4 2025), and 2414000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Protalix BioTherapeutics | 189.64 Mn | 178.85 Mn | 29.62 Mn | 18.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.39 Mn |
| Dec 31, 2025 | -3.58 Mn |
| Sep 30, 2025 | 2.41 Mn |
| Jun 30, 2025 | 395,000.00 |
| Mar 31, 2025 | -3.62 Mn |
| Dec 31, 2024 | 10.81 Mn |
| Sep 30, 2024 | 3.47 Mn |
| Jun 30, 2024 | -2.20 Mn |
| Mar 31, 2024 | -4.60 Mn |
| Dec 31, 2023 | -20.12 Mn |
| Sep 30, 2023 | -1.85 Mn |
| Jun 30, 2023 | 16.21 Mn |
| Mar 31, 2023 | -3.13 Mn |
| Dec 31, 2022 | -3.21 Mn |
| Sep 30, 2022 | -3.57 Mn |
| Jun 30, 2022 | -5.33 Mn |
| Mar 31, 2022 | -2.29 Mn |
| Dec 31, 2021 | -5.83 Mn |
| Sep 30, 2021 | -4.30 Mn |
| Jun 30, 2021 | -11.37 Mn |